Psoriatic Arthritis Pharmacotherapy Update

Authors: Philip J Mease

Publish Date: 2010/05/20

Volume: 12, Issue: 4, Pages: 272-280

PDF Link

Abstract

Psoriatic arthritis is a systemic disorder that causes chronic pain altered physical appearance and loss of function The clinical features are diverse but the core manifestations are psoriasis peripheral arthritis axial disease enthesitis and dactylitis Our understanding about the psoriatic arthritis disease state assessment and treatment has advanced thanks to significant collaborative efforts by rheumatologists and dermatologists in the development of classification criteria outcome measures to assess the various clinical domains and treatment trials with agents also used for diseases such as rheumatoid arthritis and psoriasis In particular biologic agents especially antitumor necrosis factor agents have demonstrated significant efficacy and reasonable safety in all clinical domains of the disease resulting in amelioration of clinical symptoms inhibition of structural damage and improvement in function and quality of lifeDr Mease has received research grants from Abbott Laboratories Amgen Biogen Idec BristolMyers Squibb Centocor Genentech Roche Wyeth and Pfizer has served as a consultant for Abbott Laboratories Amgen Biogen Idec BristolMyers Squibb Centocor Genentech Roche UCB Wyeth and Pfizer and has served as a speaker for Abbott Laboratories Amgen Biogen Idec BristolMyers Squibb Centocor Genentech UCB Wyeth and Pfizer

Keywords: